These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Diethylstilbestrol as a "morning after" contraceptive.
    Journal: Med Lett Drugs Ther; 1973 Jun 06; 15(14):58-9. PubMed ID: 4740292.
    Abstract:
    Diethylstilbestrol (DES) is a nonsteroidal synthetic estrogen. It has been approved as a "morning-after" contraceptive. It is thought to interfere with the implantation of the fertilized ovum. Among 5593 women treated with DES or other estrogens, 26 pregnancies have been reported. Most of these patients reported midcycle exposures. Of 92 patients with adenocarcinoma of the vagina or cervix, prenatal histories of 66 were obtained. The mothers of 49 of them had taken DES or related nonsteroidal estrogens during pregnancy. In 1 case the mother had received only 1.5 mg daily. Another mother was treated for only 5 days during the first trimester. There is no evidence that the use of DES increases the risk of cancer in the mother. The Food and Drug Administration has approved the use of DES as an emergency treatment only. Early therapeutic abortion is recommended when this use of DES fails, because of the possibility of a teratogenic effect. The recommended oral dosage is 25 mg twice daily for 5 consecutive days, begun within 72 hours after sexual exposure. Severe nausea and vomiting may occur. Headaches and menstrual irregularities have also been reported.
    [Abstract] [Full Text] [Related] [New Search]